% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Baumert:1052211,
author = {Baumert, Brigitta G. and P. M. Jaspers, Jaap and Keil, Vera
C. and Galldiks, Norbert and Izycka-Swieszewska, Ewa and
Timmermann, Beate and Grosu, Anca L. and Minniti, Giuseppe
and Ricardi, Umberto and Dhermain, Frédéric and Weber,
Damien C. and van den Bent, Martin and Rudà, Roberta and
Niyazi, Maximilian and Erridge, Sara},
title = {{ESTRO}-{EANO} guideline on target delineation and
radiotherapy for {IDH}-mutant {WHO} {CNS} grade 2 and 3
diffuse glioma},
journal = {Radiotherapy and oncology},
volume = {202},
issn = {0167-8140},
address = {Amsterdam [u.a.]},
publisher = {Elsevier Science},
reportid = {FZJ-2026-00839},
pages = {110594 -},
year = {2025},
note = {No funding has been received for the development of these
guidelines.},
abstract = {Purpose: This guideline will discuss radiotherapeutic
management of IDH-mutant grade 2 and grade 3 diffuse glioma,
using the latest 2021 WHO (5th) classification of brain
tumours focusing on: imaging modalities, tumour volume
delineation, irradiation dose and fractionation.Methods: The
ESTRO Guidelines Committee, CNS subgroup, nominated 15
European experts who identified questions for this
guideline. Four working groups were established addressing
specific questions concerning imaging, target volume
delineation, radiation techniques and fractionation. A
literature search was performed, and available literature
was discussed. A modified two-step Delphi process was used
with majority voting resulted in a decision or highlighting
areas of uncertainty.Results: Key issues identified and
discussed included imaging needed to define target
definition, target delineation and the size of margins, and
technical aspects of treatment including different planning
techniques such as proton therapy.Conclusions: The GTV
should include any residual tumour volume after surgery, as
well as the resection cavity. Enhancing lesions on T1
imaging should be included if they are indicative of
residual tumour. In grade 2 tumours, T2/FLAIR abnormalities
should be included in the GTV. In grade 3 tumours, T2/FLAIR
abnormalities should also be included, except areas that are
considered to be oedema which should be omitted from the
GTV. A GTV to CTV expansion of 10 mm is recommended in grade
2 tumours and 15 mm in grade 3 tumours. A treatment dose of
50.4 Gy in 28 fractions is recommended in grade 2 tumours
and 59.4 Gy in 33 fractions in grade 3 tumours. Radiation
techniques with IMRT are the preferred approach.Keywords:
Anaplastic glioma; Delineation; IDH-mutant diffuse glioma;
Low grade glioma; Radiotherapy; Target volume.},
cin = {INM-3},
ddc = {610},
cid = {I:(DE-Juel1)INM-3-20090406},
pnm = {5252 - Brain Dysfunction and Plasticity (POF4-525)},
pid = {G:(DE-HGF)POF4-5252},
typ = {PUB:(DE-HGF)16},
doi = {10.1016/j.radonc.2024.110594},
url = {https://juser.fz-juelich.de/record/1052211},
}